“Too many people are still dying of cancer,” he says. “The success rate of our traditional chemotherapy has not been enough, so I think the key is to understand as much as you can about the disease. And we can do that if it is through a combination of these sequencing technologies. After we’ve done that, we’ll be able to tailor toward individual alterations in cancer cells.”
